Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)

Intergroupe Francophone de Cancerologie Thoracique

Status and phase: Completed; Phase 2

Conditions: Stage III Non-small Cell Lung Cancer

Treatments: Drug: Chemotherapy; Drug: ERBITUX; Radiation: Radiotherapy

Study type: Interventional

Funder types: Other

Identifiers

NCT01102231

IFCT-0803

Details and patient eligibility

About

Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and pemetrexed) with concurrent radiotherapy.

Enrollment: 106 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• non-squamous stage III non-small cell lung cancer
• measurable disease (RECIST 1.1)
• ECOG performance status 0-1
• normal organ and marrow function

Exclusion criteria

• prior chest radiation therapy
• history of any cancer other than NSCLC (except non-melanoma skin cancer or carcinoma in situ of the cervix) within the last five years.
• Prior therapy with known specific inhibitors of the EGFR.
• history of severe allergic reaction to prior therapy with monoclonal antibodies

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

106 participants in 1 patient group

A

Experimental group

Description:

Chemoradiotherapy

Treatment:

Drug: Chemotherapy

Drug: ERBITUX

Radiation: Radiotherapy